Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 4Lymphoid 4Breast 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1NET 1Gastrointestinal 1Endocrine 1Classical hematology 1

Conditions

Neoplasms 4Neoplasm Metastasis 2Carcinoma 1

Interventions

Surveys and Questionnaires 65pembrolizumab 56Gemcitabine 54Paclitaxel 51Blood Specimen Collection 45Carboplatin 44Bevacizumab 41Docetaxel 38Cisplatin 33Nivolumab 32Fluorouracil 31Capecitabine 28Radiotherapy 25Pemetrexed 25Irinotecan 25Standard of Care 24Interviews as Topic 24Magnetic Resonance Spectroscopy 23Leucovorin 22Erlotinib Hydrochloride 22atezolizumab 21Cetuximab 21Afatinib 21Oxaliplatin 19trametinib 18Exercise 18Ipilimumab 17Sorafenib 16Cyclophosphamide 16olaparib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasms × pegfilgrastim × Tumor-Agnostic × Clear all
NCT01214629 2018-08-06

A Study for Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
54 enrolled 23 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01214642 2018-08-06

A Dose-Escalation Study for Patients With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
63 enrolled 23 charts
Tumor-Agnostic

Neoplasms

NCT00751894 2011-01-19

MEG-5

University Hospital, Clermont-Ferrand

Phase 2 Unknown
30 enrolled
Tumor-Agnostic

Neoplasms

NCT00695370 2008-06-13

Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children

University Hospital, Clermont-Ferrand

Phase 2 Terminated
30 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡